KRAS and familial pancreatic carcinoma: Lastly, it has been shown that dual targeting of the MAP kinase pathway and the autophagy pathway—especially in cancer with a high prevalence of KRAS mutation, such as pancreatic cancer—may result in increased tumor killing by inhibitors of the MAP kinase pathway by blocking autophagy, which could serve as a key mechanism of resistance.